161 related articles for article (PubMed ID: 21933682)
21. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells.
Chen N; Reith ME
J Neurochem; 2007 Apr; 101(2):377-88. PubMed ID: 17250655
[TBL] [Abstract][Full Text] [Related]
22. Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles.
Mandela P; Chandley M; Xu YY; Zhu MY; Ordway GA
Neurochem Int; 2010; 56(6-7):760-7. PubMed ID: 20176067
[TBL] [Abstract][Full Text] [Related]
23. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a recombinant human dopamine transporter in multiple cell lines.
Eshleman AJ; Neve RL; Janowsky A; Neve KA
J Pharmacol Exp Ther; 1995 Jul; 274(1):276-83. PubMed ID: 7616409
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.
Jarkas N; McConathy J; Voll RJ; Goodman MM
J Med Chem; 2005 Jun; 48(13):4254-65. PubMed ID: 15974579
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and autoradiographic evaluation of [(18)F]FE@CIT: a Comparison with [(123)I]beta-CIT and [(123)I]FP-CIT.
Ettlinger DE; Häusler D; Wadsak W; Girschele F; Sindelar KM; Mien LK; Ungersböck J; Viernstein H; Kletter K; Dudczak R; Mitterhauser M
Nucl Med Biol; 2008 May; 35(4):475-9. PubMed ID: 18482685
[TBL] [Abstract][Full Text] [Related]
27. Functional importance of the C-terminus of the human norepinephrine transporter.
Distelmaier F; Wiedemann P; Brüss M; Bönisch H
J Neurochem; 2004 Nov; 91(3):537-46. PubMed ID: 15485485
[TBL] [Abstract][Full Text] [Related]
28. Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain.
Kung MP; Choi SR; Hou C; Zhuang ZP; Foulon C; Kung HF
Nucl Med Biol; 2004 Jul; 31(5):533-41. PubMed ID: 15219270
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-substituted-6-amino-5-phenylbicyclo[2.2.2]octanes.
Javanmard S; Deutsch HM; Collard DM; Kuhar MJ; Schweri MM
J Med Chem; 1999 Nov; 42(23):4836-43. PubMed ID: 10579846
[TBL] [Abstract][Full Text] [Related]
30. Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
Zavosh A; Schaefer J; Ferrel A; Figlewicz DP
Brain Res Bull; 1999 Jul; 49(4):291-5. PubMed ID: 10424850
[TBL] [Abstract][Full Text] [Related]
31. The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.
Zhu MY; Kyle PB; Hume AS; Ordway GA
Neurochem Res; 2004 Feb; 29(2):419-27. PubMed ID: 15002740
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
Paczkowski FA; Bönisch H; Bryan-Lluka LJ
Pharmacogenetics; 2002 Mar; 12(2):165-73. PubMed ID: 11875370
[TBL] [Abstract][Full Text] [Related]
33. Extracellular loop 3 of the noradrenaline transporter contributes to substrate and inhibitor selectivity.
Lynagh T; Khamu TS; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jan; 387(1):95-107. PubMed ID: 24081522
[TBL] [Abstract][Full Text] [Related]
34. Effects of chronic cocaine self-administration on norepinephrine transporters in the nonhuman primate brain.
Beveridge TJ; Smith HR; Nader MA; Porrino LJ
Psychopharmacology (Berl); 2005 Aug; 180(4):781-8. PubMed ID: 15739079
[TBL] [Abstract][Full Text] [Related]
35. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J
PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295
[TBL] [Abstract][Full Text] [Related]
36. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.
Morón JA; Brockington A; Wise RA; Rocha BA; Hope BT
J Neurosci; 2002 Jan; 22(2):389-95. PubMed ID: 11784783
[TBL] [Abstract][Full Text] [Related]
37. Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content.
Wehrwein EA; Parker LM; Wright AA; Spitsbergen JM; Novotny M; Babankova D; Swain GM; Habecker BA; Kreulen DL
Am J Physiol Regul Integr Comp Physiol; 2008 Sep; 295(3):R857-63. PubMed ID: 18565836
[TBL] [Abstract][Full Text] [Related]
38. Noradrenergic terminals are the primary source of α
Devoto P; Flore G; Saba P; Scheggi S; Mulas G; Gambarana C; Spiga S; Gessa GL
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():97-103. PubMed ID: 30472147
[TBL] [Abstract][Full Text] [Related]
39. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects.
Belej T; Manji D; Sioutis S; Barros HM; Nobrega JN
Brain Res; 1996 Oct; 736(1-2):287-96. PubMed ID: 8930335
[TBL] [Abstract][Full Text] [Related]
40. Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.
Zhao Z; Baros AM; Zhang HT; Lapiz MD; Bondi CO; Morilak DA; O'Donnell JM
Neuropsychopharmacology; 2008 Dec; 33(13):3190-200. PubMed ID: 18418364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
